Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
<h4>Background</h4>Real-world clinical data on psoriasis patients receiving different biological agents is needed, especially in Asian populations.<h4>Objectives</h4>Our aim is to compare and analyze the efficacy and safety profile of four biological agents (etanercept, adali...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0244620 |
| _version_ | 1818740675760357376 |
|---|---|
| author | Yu-Chen Chen Yi-Ting Huang Chao-Chun Yang Edward Chia-Cheng Lai Cheng-Han Liu Chao-Kai Hsu Tak-Wah Wong Sheau-Chiou Chao Hamm-Ming Sheu Chaw-Ning Lee |
| author_facet | Yu-Chen Chen Yi-Ting Huang Chao-Chun Yang Edward Chia-Cheng Lai Cheng-Han Liu Chao-Kai Hsu Tak-Wah Wong Sheau-Chiou Chao Hamm-Ming Sheu Chaw-Ning Lee |
| author_sort | Yu-Chen Chen |
| collection | DOAJ |
| description | <h4>Background</h4>Real-world clinical data on psoriasis patients receiving different biological agents is needed, especially in Asian populations.<h4>Objectives</h4>Our aim is to compare and analyze the efficacy and safety profile of four biological agents (etanercept, adalimumab, ustekinumab and secukinumab) in a real-world setting in Taiwan.<h4>Methods</h4>We retrospectively analyzed the clinical data of all patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥ 10) who received etanercept, adalimumab, ustekinumab or secukinumab between January 2011 and December 2018 in a tertiary hospital in Taiwan.<h4>Results</h4>A total of 119 treatment episodes in 75 patients were included in this study. Ustekinumab was used in 49 treatment episodes, followed by secukinumab in 46 treatment episodes, adalimumab in 14 treatment episodes and etanercept in 10 treatment episodes. The proportion of the biologic-naïve was highest in etanercept (100%) and lowest in secukinumab (23.9%). The PASI-75, -90 and -100 were the highest in secukinumab (91.3%, 82.6%, 41.3%, respectively), followed by ustekinumab (79.6%, 44.9%, 16.3%), adalimumab (64.3%, 28.6%, 7.1%) and etanercept (50.0%, 30.0%, 0%). The rate of adverse events that required treatment was highest for secukinumab (15.2%), followed by adalimumab (14.3%), ustekinumab (8.2%), and etanercept (0%), including 4 cases of infections, 2 cases of cardiovascular diseases and 4 cases of cancers.<h4>Conclusions</h4>This real world data showed differential efficacy and safety of the four biological agents. |
| first_indexed | 2024-12-18T01:44:30Z |
| format | Article |
| id | doaj.art-9d9b0a4a870c42b49534adbcaf3bb0a8 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-18T01:44:30Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9d9b0a4a870c42b49534adbcaf3bb0a82022-12-21T21:25:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-011512e024462010.1371/journal.pone.0244620Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.Yu-Chen ChenYi-Ting HuangChao-Chun YangEdward Chia-Cheng LaiCheng-Han LiuChao-Kai HsuTak-Wah WongSheau-Chiou ChaoHamm-Ming SheuChaw-Ning Lee<h4>Background</h4>Real-world clinical data on psoriasis patients receiving different biological agents is needed, especially in Asian populations.<h4>Objectives</h4>Our aim is to compare and analyze the efficacy and safety profile of four biological agents (etanercept, adalimumab, ustekinumab and secukinumab) in a real-world setting in Taiwan.<h4>Methods</h4>We retrospectively analyzed the clinical data of all patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥ 10) who received etanercept, adalimumab, ustekinumab or secukinumab between January 2011 and December 2018 in a tertiary hospital in Taiwan.<h4>Results</h4>A total of 119 treatment episodes in 75 patients were included in this study. Ustekinumab was used in 49 treatment episodes, followed by secukinumab in 46 treatment episodes, adalimumab in 14 treatment episodes and etanercept in 10 treatment episodes. The proportion of the biologic-naïve was highest in etanercept (100%) and lowest in secukinumab (23.9%). The PASI-75, -90 and -100 were the highest in secukinumab (91.3%, 82.6%, 41.3%, respectively), followed by ustekinumab (79.6%, 44.9%, 16.3%), adalimumab (64.3%, 28.6%, 7.1%) and etanercept (50.0%, 30.0%, 0%). The rate of adverse events that required treatment was highest for secukinumab (15.2%), followed by adalimumab (14.3%), ustekinumab (8.2%), and etanercept (0%), including 4 cases of infections, 2 cases of cardiovascular diseases and 4 cases of cancers.<h4>Conclusions</h4>This real world data showed differential efficacy and safety of the four biological agents.https://doi.org/10.1371/journal.pone.0244620 |
| spellingShingle | Yu-Chen Chen Yi-Ting Huang Chao-Chun Yang Edward Chia-Cheng Lai Cheng-Han Liu Chao-Kai Hsu Tak-Wah Wong Sheau-Chiou Chao Hamm-Ming Sheu Chaw-Ning Lee Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. PLoS ONE |
| title | Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. |
| title_full | Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. |
| title_fullStr | Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. |
| title_full_unstemmed | Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. |
| title_short | Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan. |
| title_sort | real world efficacy of biological agents in moderate to severe plaque psoriasis an analysis of 75 patients in taiwan |
| url | https://doi.org/10.1371/journal.pone.0244620 |
| work_keys_str_mv | AT yuchenchen realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT yitinghuang realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT chaochunyang realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT edwardchiachenglai realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT chenghanliu realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT chaokaihsu realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT takwahwong realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT sheauchiouchao realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT hammmingsheu realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan AT chawninglee realworldefficacyofbiologicalagentsinmoderatetosevereplaquepsoriasisananalysisof75patientsintaiwan |